Pharmacology of the short QT syndrome N588K-hERG K(+) channel mutation: differential impact on selected class I and class III antiarrhythmic drugs

Antzeko izenburuak

• Increased Vulnerability of Human Ventricle to Re-entrant Excitation in hERG-linked Variant 1 Short QT Syndrome
  nork: Adeniran, Ismail, et al.
  Argitaratua: (2011)
• hERG1a/1b heteromeric currents exhibit amplified attenuation of inactivation in variant 1 short QT syndrome
  nork: McPate, M.J., et al.
  Argitaratua: (2009)
• Action Potential Clamp and Pharmacology of the Variant 1 Short QT Syndrome T618I hERG K(+) Channel
  nork: El Harchi, Aziza, et al.
  Argitaratua: (2012)
• Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
  nork: Aziza El Harchi, et al.
  Argitaratua: (2012-01-01)
• Functional and pharmacological characterization of an S5 domain hERG mutation associated with short QT syndrome
  nork: Butler, Andrew, et al.
  Argitaratua: (2019)